Advances and controversies in the management of early stage non-small cell lung cancer.
World J Clin Oncol
; 12(12): 1089-1100, 2021 Dec 24.
Article
em En
| MEDLINE
| ID: mdl-35070733
ABSTRACT
Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lower recurrence and metastasis rates than sublobar resection and lower postoperative morbidity and mortality than pneumonectomy. There is a growing tendency to perform sublobar resection in selected cases, as, depending on factors such as tumor size, histologic subtype, lymph node involvement, and resection margins, it can produce similar oncological results to lobectomy. Alternative treatments such as stereotactic body radiotherapy and radiofrequency ablation can also produce good outcomes in inoperable patients or patients who refuse surgery.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
World J Clin Oncol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Espanha